Portland State University

PDXScholar

Chemistry Faculty Publications and
Presentations

Chemistry

8-6-2008

Synthesis and Relaxometric Studies of a Dendrimer-Based pH-Responsive MRI Contrast Agent

M. Meser Ali

University of Texas at Dallas

Mark Woods

Portland State University, mark.woods@pdx.edu

Peter Caravan

A.A. Martinos Center for Biomedical Imaging

Ana C.L. Opina

University of Texas at Dallas

Marga Spiller

New York Medical College

Follow this and additional works at: https://pdxscholar.library.pdx.edu/chem_fac

See next page for additional authors

Part of the [Chemistry Commons](#)

Let us know how access to this document benefits you.

Citation Details

Ali, M. M., Woods, M., Caravan, P., Opina, A. C., Spiller, M., Fettingner, J. C., & Sherry, A. D. (2008). Synthesis and relaxometric studies of a dendrimer-based pH-responsive MRI contrast agent. *Chemistry—A European Journal*, 14(24), 7250-7258.

This Post-Print is brought to you for free and open access. It has been accepted for inclusion in Chemistry Faculty Publications and Presentations by an authorized administrator of PDXScholar. Please contact us if we can make this document more accessible: pdxscholar@pdx.edu.

Authors

M. Meser Ali, Mark Woods, Peter Caravan, Ana C.L. Opina, Marga Spiller, James C. Fettingner, and A. Dean Sherry

Synthesis and Relaxometric Studies of a Dendrimer-Based pH-Responsive MRI Contrast Agent

M. Meser Ali^a, Mark Woods^{a,b}, Peter Caravan [Prof.]^c, Ana C. L. Opina^a, Marga Spiller^d, James C. Fetting^e, and A. Dean Sherry [Prof.]^{a,f}

M. Meser Ali: ; Mark Woods: ; Peter Caravan: ; Ana C. L. Opina: ; Marga Spiller: ; James C. Fetting: ; A. Dean Sherry: dean.sherry@utsouthwestern.edu

^aDepartment of Chemistry, University of Texas at Dallas, P.O. Box 830660, Richardson, Texas 75083 (USA)

^bMacrocyclics, 2110 Research Row, Suite 425, Dallas, Texas 75235 (USA)

^cA.A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129 (USA)

^dDepartment of Radiology, New York Medical College, Valhalla, New York 10595 (USA)

^eDepartment of Chemistry, University of California at Davis, One Shields Avenue, Davis, CA 95616-5298 (USA)

^fAdvanced Imaging Research Center, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390 (USA), Fax: (+1) 214-645-2744

Abstract

The design of effective pH responsive MRI contrast agents is a key goal in the development of new diagnostic methods for conditions such as kidney disease and cancer. A key factor determining the effectiveness of an agent is the difference between the relaxivity of the “on” state compared to that of the “off” state. In this paper, we demonstrate that it is possible to improve the pH-responsive action of a low molecular weight agent by conjugating it to a macromolecular construct. The synthesis of a bifunctional pH responsive agent is reported. As part of that synthetic pathway we examine the Ing–Manske reaction, identifying an undesirable by-product and establishing effective conditions for promoting a clean and effective reaction. Reaction of the bifunctional pH responsive agent with a G5-PAMAM dendrimer yielded a product with an average of 96 chelates per dendrimer. The relaxivity of the dendrimer conjugate rises from 10.8 mm⁻¹ s⁻¹ (pH 9) to 24.0 mm⁻¹ s⁻¹ (pH 6) per Gd³⁺ ion. This more than doubles the relaxivity pH response, Δr_1 , of our agent from just 51% for the original low molecular weight chelate to 122% for the dendrimer.

Keywords

dendrimers; imaging agents; lanthanide complexes; MRI contrast agents

Introduction

Diseases, such as kidney disorders and cancer, often result in a significant reduction in the extracellular pH of these tissues.[1–3] Thus, imaging tissue pH could be quite useful in clinical diagnose of these and other conditions. Current methods for assessing tissue pH involve relatively invasive procedures and typically can assess pH only from a limited number of locations.[2–4] Less invasive techniques such as ^{31}P NMR spectroscopy[4] can provide a direct measure of pH but the concentrations of the endogenous phosphorus metabolites that respond to tissue pH are relatively low so pH measurements can only be taken from relatively large volumes of tissue. pH sensitive fluorescence dyes are quite sensitive but applications of optical techniques in human imaging is limited to tissues near the surface of skin where sufficient light penetration can be achieved.[4] A pH responsive T_1 -shortening contrast agent could offer a minimally invasive and highly practical approach to mapping of tissue pH so it is hardly surprising that a large number of pH sensitive MRI contrast agents have been reported. [5–13]

Typically, Gd^{3+} -based complexes used to relax bulk water have relatively low T_1 relaxivities. Relaxivity is defined as the increase in water proton relaxation rate per unit concentration of contrast agent and is a measure of the effectiveness of a contrast agent. At typical magnetic fields used for clinical imaging, the relaxivity of a Gd^{3+} complex is primarily determined by three factors: q , the number of water molecules in the inner coordination sphere of Gd^{3+} ; τ_M , the residence lifetime of these water molecule on Gd^{3+} ; and τ_R , the rotational correlation time, or how fast the complex tumbles in solution.[14–18] Examples of contrast agents that respond to pH through changes in each of these parameters have been reported,[5] but the only agent actually used to image tissue pH to date is **Gd1** (see below).[12,13] Although **Gd1** exhibits a relatively small a change in relaxivity over a physiologically relevant pH range, it has been used successfully in vivo to generate pH maps of kidneys and tumors in small animals.[19–21] The mechanism by which **Gd1** operates as a pH responsive agent is unique among responsive Gd^{3+} agents and stems from the presence of the phosphonate groups of the pendant arms.[12] The sole inner-sphere water molecule of **Gd1** is in slow exchange with the bulk solvent which, ordinarily, would limit relaxivity. However, the phosphonate groups of **Gd1** are able to catalyse the exchange of the protons of this single Gd^{3+} -bound water molecule with bulk solvent protons. The effectiveness of the phosphonates at catalysing proton exchange is dependent upon their protonation state so as the four phosphonates become successively protonated at the pH falls below ≈ 8.5 , the rate of proton exchange increases and the paramagnetic relaxation effects of Gd^{3+} are transferred to the bulk solvent protons. In addition the phosphonates can organise a number of other water molecules into a second hydration sphere through hydrogen-bonding interactions.[22,23] The extent, and proton residence lifetime, of this second hydration sphere is also likely to fluctuate with the protonation state of the phosphonate groups. The increase in relaxivity of **Gd1** on passing from pH 9 to 6 was found to be the result of a combination of these two effects.[12]

Despite the demonstrated utility of Gd1, the maximum increase in relaxivity with changing pH, Δr_1 , is relatively modest, rising from $3.5 \text{ mM}^{-1} \text{ s}^{-1}$ at pH 9.5 to $5.3 \text{ mM}^{-1} \text{ s}^{-1}$ at pH 6.3; a Δr_1 of just 51%. [12] The relaxivity arising from an exchanging inner-sphere water molecule, $r_1^{\text{i.s.}}$, is given by Equation (1), where τ_M is the lifetime of the inner-sphere bound water molecule and T_{1M} is the T_1 of the inner-sphere water protons. The relaxivity arising from water molecules in the second hydration sphere follows a similar relationship. From Equation (1) it can be seen that relaxivity will be higher if T_{1M} is shorter, but the rapid rotational dynamics of Gd1 cause T_{1M} to be long thereby limiting relaxivity.

$$r_1^{\text{i.s.}} = \frac{1}{55.6} \left(\frac{q}{T_{1M} + \tau_M} \right) \quad (1)$$

Slowing molecular rotation is most easily achieved by conjugating the contrast agent to a macromolecule, such as a dendrimer. However, improving relaxivity alone will not improve the function of Gd1 as a pH responsive contrast agent. To do that it is necessary to accentuate the difference between the high and low relaxivity regimes. We hypothesized that T_{1M} could be reduced by conjugating Gd1 to a dendrimer which would render the system more sensitive to changes in τ_M . At higher pH values, the relaxivity would be expected to be limited by slow exchange whereas at lower pH values, catalysis of inner-sphere proton exchange by the phosphonate groups should lift the limiting effect of exchange upon relaxivity ($T_{1M} > \tau_M$). Overall, coupling Gd1 to the dendrimer should improve both the absolute relaxivity, r_1 , and the change in relaxivity, Δr_1 , on going from low to high pH. We therefore set out to conjugate Gd1 to a larger macromolecule, in this case an ethylenediamine core G5-PAMAM dendrimer, in order to reduce the rate of rotation and improve the pH responsive characteristics of the complex.

Results and Discussion

Synthesis

As the phosphonate groups of the pendant arms were found to be responsible for the pH responsive nature of Gd1, [12] it was important to maintain this structural feature when the

complex was modified to facilitate attachment to the dendrimer. Accordingly, the complex was modified by incorporating a functionalized benzyl group onto the macro-cyclic backbone of the complex, leaving the four phosphonate groups intact. The functionalized complex Gd2 was prepared following the same synthetic procedure used for the preparation of Gd1[12] simply substituting (*S*)-2-(*p*-nitrobenzyl) cyclen for cyclen (Scheme 1).

Compound **3** was prepared by the Michaelis–Arbuzov reaction of triethylphosphite with bromomethyl phthalimide. The key intermediate **4** was then obtained by removal of the phthalimide protecting group by an Ing–Manske[24] reaction with 1.2 equivalents of hydrazine in ethanol. Normally this type of deprotection reaction proceeds in good yields;[24] however, in our case the yields were moderate at best.[12] Furthermore, the presence of significant quantities of a reaction by-product meant that column chromatography was necessary to purify amine **4**, an oil at room temperature. Amines can often be purified by an acid/base extraction but **4** shows good water solubility, even at high pH, and this precluded purification by extraction. Low yielding reactions that require complicated purification procedures are unsuitable for the scale-up necessary for the production of large quantities of an MRI contrast agent. We therefore undertook an investigation into the reasons for the low reaction yield of this step.

¹H NMR analysis of the crude reaction mixture indicated that the primary contaminant of the product **4** was a single reaction by-product. This compound was isolated by column chromatography and characterized. Rather surprisingly, this by-product was identified as compound **5**, the product of a reaction between the starting material **3** and the intended reaction product **4** (Scheme 2). A significant effort has been applied to understanding the mechanism and intermediates of the Ing–Manske reaction,[25–28] however, this particular reaction pathway is rarely included in these discussions.[29] The quantities of **5** produced suggest that this side reaction may, on occasion, be more important than generally described. The mechanism of the Ing–Manske reaction is quite complex[26–29] but it is initiated by nucleophilic attack of hydrazine at one of the carbonyls of the phthalimide. The effectiveness of an amine at removing phthalimide protecting groups has been shown to relate to the protonation constant of the attacking amine; the more basic the amine, the more effective the reaction.[27] Thus, if the product amine is significantly more basic than hydrazine, it is likely to compete with hydrazine in attacking the phthalimide **3** to yield significant quantities of compound **5**.

The identity of compound **5** was established by NMR spectroscopy and mass spectrometry and, although attempts to remove compound **5** from the crude reaction mixture by crystallisation were unsuccessful, compound **5** readily crystallises once purified. X-ray quality crystals could be grown at room temperature from a solution of **5** in dichloromethane by addition of diethyl ether and hexanes. This allowed the structure of compound **5** to be confirmed by X-ray crystallography (Figure 1). The production of compound **5** during the deprotection of the phthalimide **3** is doubly detrimental to the yield of **4** since two molecules of **4** are taken up into one molecule of **5**; this is in addition to the need for chromatography. Thus, eliminating compound **5** from the reaction would both improve yield and simplify purification since the other reaction by-product, the insoluble phthalhydrazide, can be removed by filtration. A number of improvements to the Ing–Manske reaction have been suggested, most notably raising the reaction pH through addition of sodium hydroxide.[26,27] However, concerns over the lability of the phosphonate diester moiety towards base-catalysed hydrolysis precluded this as a solution to this problem. We investigated a number of the other Ing–Manske reaction conditions to assess whether the reaction conditions could be improved.

Compounds **4** and **5** are easily distinguished by ¹H NMR spectroscopy; a shift difference of almost 1 ppm is observed for the methylene resonance α to the phosphorous. This resonance

appears as a doublet at 2.9 ppm (coupled to phosphorous) in **4** and as a doublet of doublets at 3.8 ppm (coupled to phosphorous and the amide proton) in **5**. A series of experiments were performed in which various reaction conditions were altered and the ratio of the two reaction products in the crude reaction mixture determined by ^1H NMR spectroscopy. Neither increasing the reaction temperature from room temperature to reflux nor increasing the reaction time from 6 h to 5 d was found to have a significant effect upon the distribution of reaction products. However, when the amount of hydrazine used in the reaction was increased the amount of **4** obtained from the reaction was greatly increased at the expense of **5**. Increasing the amount of hydrazine from one to four equivalents greatly reduced the amount of **5** produced in the reaction. At six equivalents of hydrazine the yield of **5** was < 5%, and ten equivalents of hydrazine eliminated all traces of **5** from the reaction ^1H NMR spectrum. This observation does not indicate that **5** is not produced during the reaction. Indeed, when a purified sample of **5** was treated with ten equivalents of hydrazine it was found to undergo a quantitative conversion to **4**, as determined by ^1H NMR (Scheme 2). Thus, **5** may still be produced in the reaction but, importantly, it is reactive under these conditions and does not persist as a reaction product.

Changing the conditions of the Ing–Manske reaction by increasing to ten the equivalents of hydrazine allowed purification to be simplified from column chromatography to filtration to remove the phthalhydrazide. It also improved the reaction yield to 97% and rendered this process suitable for scale-up. Condensation of the amine **4** with bromoacetyl bromide afforded the bromoacetamide **6** which was used to alkylate (*S*)-2-(*p*-nitrobenzyl) cyclen in acetonitrile with K_2CO_3 as base (Scheme 1). Subsequent deprotection of the phosphonate esters of **7** with HBr in AcOH afforded the ligand **2** a functionalized analogue of **1** that preserved the integrity of the four phosphonate groups.

It was later found that conjugation of the bifunctional ligand to the PAMAM dendrimer was more efficient if the protected ester ligand **7** was used instead of the free acid. Reduction of the nitro group with hydrogen and palladium catalyst afforded the corresponding amine **8** in 72% yield (Scheme 3). The amine was then converted to the isothiocyanate **9** by reaction with thiophosgene in a biphasic reaction at pH 2. The isothiocyanate group is ideal for conjugation with primary amines, such as those that decorate the surface of the PAMAM dendrimer, under mild conditions. The phosphonate ester was preferred for this conjugation reaction in order to minimize non-reactive salt formation between the amines of the dendrimer and phosphonic acids and repulsion between conjugated and incoming phosphonates. The ethylenediamine core G5-PAMAM dendrimer selected as the basis of our macromolecular construct has 128 primary amine groups on its surface. The dendrimer was reacted with 256 equivalents of **9** for 24 h at 40 °C followed by a further 256 equivalents for 48 h. The reaction pH was maintained at 9 throughout by addition of a 1 M solution of NaOH. The reaction was analysed by HPLC using a Phenomenex BIOSEP SEC S-3000 size exclusion column (5–700 kD, PBS buffer, pH 7.4). The chelate–dendrimer conjugate was purified by repeated diafiltration using a Centricon C-30 membrane with a 30 kD cut-off (Millipore) until no low molecular weight materials could be detected by HPLC. HPLC analysis of the resulting dendrimer indicated that an average hydrodynamic volume equating to a molecular weight of about 140 kD was achieved. This corresponds to an average of 75% coverage or 96 ligands per dendrimer. A ligand/dendrimer coverage ratio of 97:1 was confirmed by elemental analysis of the carbon and sulfur content of the conjugate. Similar loading values were obtained by ^1H NMR analysis of the aromatic and alkyl protons, however, the reproducibility of loading values determined by this method was poorer than SEC and combustion analysis. The conjugation reaction was performed in H_2O , DMSO and mixtures of the two, the extent of ligand/dendrimer ratio was found to be unaffected by the choice of solvent. The phosphonate esters of the conjugate **10** were finally removed under identical conditions to those used in the preparation of the ligand **2**, HBr and AcOH, to afford the conjugate **11**.

Formation of the gadolinium complexes of **2** and **11** also requires special attention. With most DOTA-tetraamide ligands, this step is relatively simple; however, we have recently reported that the phosphonate groups of **1** can interfere with these complexation reactions[12] so care was taken to perform the complexation reactions of both **2** and **11** at pH 9 in order to ensure that the gadolinium ion was bound by the macrocyclic coordination cage. In the case of ligand **2** equimolar amounts of ligand and gadolinium chloride hexahydrate were reacted together at pH 9 and 60 °C in aqueous solution. No further purification was undertaken. However, 1.2 equivalents of gadolinium chloride were used in the reaction with **11** to ensure complete reaction of the ligands. After 48 h at 40 °C and pH 9 in aqueous solution the excess gadolinium was removed by addition of EDTA followed by dialysis in water (12 kD molecular weight cut-off, Sigma Aldrich). The conjugate Gd**11** was then further purified by diafiltration with Centricon C-10 (10 kD cut-off) in water at pH 7.4. Although addition of the Gd³⁺ ion into each ligand of the conjugate would lead to a substantial increase in molecular weight, this increase would be expected to have little or no effect upon the hydrodynamic volume of the conjugate. Thus, size exclusion HPLC was used to verify that the apparent molecular weight remained near 140 kD.

Relaxometric studies

The relaxivity pH profile of Gd**2** was recorded and compared with that of Gd**1** to ensure that the introduction of the benzylic function on the macrocyclic ring did not negatively impact the pH responsive properties of the complex. The relaxivity pH profiles of Gd**1** and Gd**2** (Figure 2) are comparable, rising and falling to approximately the same relaxivity at approximately the same pH. The only slight difference between the two profiles is that the relaxivity of Gd**2** is slightly higher than that of Gd**1** between pH 4 and 6. This may be a reflection of slight changes in the protonation constants of the phosphonates, but nonetheless indicates that introduction of the nitrobenzyl substituent does not negatively impact the behaviour of Gd**2**. Like Gd**1** the relaxivity of Gd**2** changes over a physiologically relevant pH range. The relaxivity pH profile of Gd**11** is also shown (Figure 2); here the advantage of conjugating the low molecular weight chelate to a dendrimer is immediately apparent. The relaxivity of Gd**11** changes over the same physiologically relevant pH range as that of Gd**1** and Gd**2** but is much higher on a per Gd³⁺ basis, rising from 10.8 mM⁻¹ s⁻¹ at pH 9.5 to 24.0 mM⁻¹ s⁻¹ at pH 6. (On a per molecule basis relaxivity rises from 1037 mM⁻¹ s⁻¹ to 2304 mM⁻¹ s⁻¹.) This equates to a relaxivity pH response, Δr_1 , of 122% on passing from pH 9.5 to 6.0, more than doubling the Δr_1 of Gd**1** and Gd**2**, Δr_1 =51 and 59%, respectively, over the same pH range. Although the pH profiles of Gd**1** and Gd**2** exhibit a drop in relaxivity on passing below pH 6 the profile of Gd**11** cannot be measured below this pH since the dendrimer conjugate precipitates from solution immediately below pH 5.9. This is presumably the result of the high molecular weight conjugate suddenly reaching its isoelectric point.

The difference in relaxivity between the “on” (pH 6) and “off” (pH 9.6) states of the dendrimer-based pH responsive agent was improved by more than a factor of 2 by slowing molecular rotation. This should render the dendrimer-conjugate, Gd**11**, a more effective pH responsive agent for imaging tissue pH. In order to assess the origins of this improvement in pH responsive behaviour, nuclear magnetic resonance dispersion (NMRD) profiles of Gd**11** were recorded at high and low pH values (Figure 3). At both pH 6.5 and at pH 9.3, the relaxivity increased at lower temperatures indicating that the observed relaxivities are not limited by slow water proton exchange between complex and bulk water. Comparing the high field (1–100 MHz) regions of NMRD profiles recorded at the same temperature we can see that at higher pH (9.3) the curve is flatter and has a lower magnitude than at lower pH (6.5). This indicates that at pH 9.3 the effective correlation time, τ_C , which is responsible for modulating relaxation, is shorter than it is at pH 6.5.

Owing to the large number of ionizable phosphonate and dendrimer amine groups on the dendrimer, multiple protonated species must exist at each pH value. This complicates any attempt to “fit” these NMRD profiles in a quantitative, meaningful way. Nonetheless, it is useful to examine the parameters that influence relaxivity in a qualitative sense in order to probe which factors are responsible for the observed behaviour. One may assume that each of the 96 Gd^{3+} chelates on the dendrimer surface has one water molecule in its inner coordination sphere. In addition, the phosphonate groups of each pendant arm may form hydrogen-bonding interactions with nearby water molecules forming a second hydration sphere. The extent of this second hydration sphere is likely to vary as the phosphonates are protonated or deprotonated with changing pH. Over a certain pH range it has also been shown that these phosphonates can catalyse exchange of protons from the coordinated water molecule to the bulk solvent.[12] Finally there is an outer-sphere contribution to relaxivity resulting from the diffusion of water molecules of the bulk solvent close by the slowly tumbling Gd^{3+} chelates. This outer-sphere effect depends primarily on the rate of diffusion of water and is insensitive to changes in pH.

Conjugating Gd^{3+} complexes to dendrimers is a common strategy for slowing the rotational dynamics of paramagnetic complexes.[30–37] In order to quantitatively describe the rotational dynamics of these dendrimer systems, the Lipari–Szabo approach is typically used.[38–43] This model employs two correlation times; a long correlation time that defines the global motion of the entire dendrimer conjugate, τ_g , and a second shorter correlation time, τ_l , that reflects the local motion of the metal complex about its point of attachment to the dendrimer. This fast local motion is superimposed upon the slower global motion of the dendrimer. For systems conjugated to G5-PAMAM dendrimers the global correlation time, τ_g , has been reported on the order of 4–5 ns.[42,44] The correlation time describing the local motion, τ_l , of the complex range from 0.07–0.76 ns.[41–44] The relative weighting of these two correlation times is given by an order parameter, S^2 , that can range from 0 (where local motion is dominant) to 1 (where isotropic, global motion is dominant). For dendrimers modified with Gd^{3+} chelates S^2 was found to range from 0.28–0.5.

We assumed that similar rotational dynamics applied to **Gd11** and these parameters to simulate the high field region (1–100 MHz) of an NMRD profile (Figure 4). Electron-spin relaxation parameters were fixed at values similar to those used elsewhere.[40–44] When the rate of proton exchange between water molecules associated with the complex (either 1st or 2nd hydration sphere) and the bulk solvent is extremely fast (short τ_M) the high field NMRD profile is flat and relaxivity low (Figure 4a). This is because these protons have a low probability of being relaxed before they exchange back into the bulk solvent. At the other extreme, very slow exchange that is, very long τ_M , the profile is also flat and relaxivity low (Figure 4b) because these protons, once relaxed by Gd^{3+} , remain on the complex preventing others from being relaxed. So in both cases relaxation is not effectively transferred to the bulk solvent and the T_1 of the bulk remains long. Between these two extremes, where $1 \text{ ns} < \tau_M < 1000 \text{ ns}$, the profile is characterized by higher relaxivities and a “hump” between 10 and 60 MHz (Figure 4). The magnitude of the relaxivity in the profiles will depend on these exchange kinetics, but also on the number of exchangeable protons and their distance from Gd^{3+} . However, these latter two parameters will not affect the shape of the NMRD profile.

In order to mimic the flat, field independent behaviour observed for **Gd11** at pH 9.3, the proton residence lifetime, τ_M , must be either very short ($<1 \text{ ns}$) or very long ($>1 \mu\text{s}$). The rate of water proton exchange is temperature dependent; as the temperature is lowered τ_M becomes longer. This increase in τ_M applies to both water molecules in the inner and second hydration spheres; however, it has an opposing effect on the relaxivity of each. The water protons of the inner-sphere water molecule of **Gd1** were found to be in slow exchange with the bulk,[12] and so these protons contribute poorly to the overall relaxivity. In contrast, water protons of a second

hydration sphere are known to undergo very rapid exchange that also limits their contribution to relaxivity.[22] Whereas making τ_M of the inner sphere longer (lower temperature) will not result in an increase in relaxivity, making τ_M of the second sphere longer could bring these protons into a range where they are able to contribute more substantially to relaxivity (Figure 4a). Inspecting the NMRD profile of Gd11 recorded at pH 9.3 and 35 °C, the high field region is flat suggesting that exchange of inner-sphere water protons is too slow and exchange of second sphere water protons too fast for a relaxivity enhancement “hump” to be observed at high field. As the temperature is taken down to 5 °C the profile begins to take on the appearance of a small “hump” at high field. Clearly exchange from the inner-sphere water protons will continue to be too slow to provide a contribution to relaxivity at lower temperatures. The small increase in relaxivity must therefore be the result of slowing the exchange rate of second-sphere water protons into a range that allows some contribution to relaxivity. This second-sphere contribution to relaxivity is not observed for either Gd1 or Gd2 because their rotational dynamics are too rapid. Given the small size of the high field relaxivity hump, exchange of second-sphere water molecules is likely to be in the range of $\tau_M=0.5\text{--}5$ ns.

Over a certain pH range, the phosphonate groups of the pendant arms of the low molecular weight complexes Gd1 and Gd2, catalyse exchange of inner-sphere water protons with the bulk solvent.[12] The fast rotational dynamics ($\tau_g \approx 0.1$ ns) of these low molecular weight chelates limits their relaxivity but conjugation to the dendrimer lifts this restriction in Gd11 and so the observed relaxivity is higher by a factor of almost 5. At pH 6.5 and 35 °C the NMRD profile of Gd11 already has a slight high field “hump” which becomes more pronounced as the temperature is lowered. From studies on Gd1, a contribution to this high field relaxivity from the inner-sphere proton exchange is expected. However, a contribution from protons in the second hydration sphere is also apparent. This is most clearly seen when the temperature is lowered. The τ_M of inner-sphere water protons of Gd1 was found to be on the order of microseconds[12] and so as the temperature is lowered the inner-sphere relaxivity should decrease as exchange becomes increasingly limited (cf. Figure 4b). The observed relaxivity increases with decreasing temperature indicating that a substantial second-sphere component must be present (Figure 4a). The fact that the increase in high field relaxivity with decreasing temperature is larger at pH 6.5 than it is at pH 9.3 suggests that either the second hydration sphere is larger or it is more ordered, leading to longer τ_M values, at pH 6.3 than at 9.3. Gd11 would seem to be a rare example of a system in which relaxivity is limited both by prototropic exchange in the 2nd-sphere that is too fast and by water exchange in the inner-sphere that is too slow.

It is worth noting that a third factor may also play a role in improving the relaxivity pH response of Gd11. Gd^{3+} complexes that exhibit no pH response have been found to behave as pH responsive agents once conjugated to PAMAM dendrimers.[44] The origin of this phenomenon is thought to be changes in the internal motion of the dendrimer itself as the pH changes. Protonation of amines within the body of the dendrimer is believed to make the dendrimer more rigid making τ_R longer at lower pH. Thus the relaxivity of agents conjugated to these dendrimers has been found to increase as the pH drops. It is likely that, in addition to the interplay of inner-sphere and second-sphere water proton exchange rates, a third contribution to the pH responsive behaviour of Gd11 arises from changes in the rigidity of the dendrimer with changes in pH.

Conclusions

It is possible to take advantage of the interplay between molecular reorientation and water proton exchange kinetics to enhance the response behaviour of complexes that exhibit changes in relaxivity arising from changes in water or proton exchange kinetics. Our initial hypothesis was that coupling the pH-responsive agent Gd1 to a dendrimer would increase both the overall

relaxivity, r_1 , the responsiveness of relaxivity to pH, Δr_1 . This was achieved by slowing rotation via conjugation to a dendrimer, increasing Δr_1 by more than a factor of 2. This enhancement should enable Gd11 to serve as an effective pH responsive MRI contrast agent. Furthermore, this dendrimer system has provided further insights into the mechanism by which this class of pH responsive agent, Gd1, Gd2 and Gd11, operates. The pH response is the result of a complex interplay between the rate of proton exchange between the bulk solvent and water molecules in the inner and second hydration spheres. The overall relaxivity is ultimately limited by the slow exchange kinetics of protons in the inner hydration sphere and rapid exchange kinetics of protons in the second hydration sphere. From an imaging point of view the substantial improvements in both r_1 and Δr_1 afforded by Gd11 should allow improved determination of in vivo pH by MRI. However, it is worth noting that improving Δr_1 through increased molecular weight may also negatively impact the effectiveness of such agents. Large molecules, such as dendrimers, remain in vasculature longer than discrete agents, such as Gd1, which are better able to diffuse into all extracellular space. Furthermore, large molecules, such as Gd11, tend to clear more slowly from the body as a result of increased liver uptake. This extends the retention time of Gd^{3+} in the body. Further studies into the in vivo behaviour of dendrimer-based MRI contrast media will be required to establish if this approach, which is successful for increasing both r_1 and Δr_1 , will yield agents that can actually be applied in vivo.

Experimental Section

General remarks

All reagents and solvents were purchased from commercial sources and used as received unless otherwise stated. The ethylene core G5-PAMAM dendrimer from Dendritech was purchased through Sigma-Aldrich as a 5% solution in methanol. Prior to use the solvents were removed under vacuum and the dendrimer redissolved in the reaction solvent. ^1H NMR spectra were recorded on a JOEL Eclipse 270 spectrometer operating at 270.17 MHz, a Varian Mercury 300 spectrometer operating at 299.95 MHz and a Bruker Avance III spectrometer operating at 400.13 MHz. ^{13}C NMR spectra were obtained using a Bruker Avance III spectrometer operating at 100.61 MHz. Longitudinal relaxation times were measured using the inversion recovery method on a MRS-6 NMR analyzer from the Institut "Jožef Stefan", Ljubljana, Slovenia operating at 20 MHz. The pH of samples for relaxivity measurements was adjusted by addition of either lithium hydroxide monohydrate or *p*-toluenesulfonic acid monohydrate in order to avoid dilution. Melting points were determined on a Fisher-Johns melting point apparatus and are uncorrected. NMRD profiles between 0.01 and 50 MHz were recorded using the field cycling relaxometer at New York Medical College, Valhalla NY.

Synthesis

The synthesis of diethyl phthalimidomethylphosphonate (**3**) and diethyl bromoacetamidomethylphosphonate (**6**) have been reported previously.[12]

Diethyl aminomethylphosphonate (**4**)

Hydrazine (81.6 mL, 168.2 mmol) was added to a solution of the phthalimide **3** (50.0 g, 1.68 mol) in dry ethanol (500 mL). The reaction was stirred at room temperature for 18 h. The solvents were removed under reduced pressure and the residue placed under high vacuum to remove as much excess hydrazine as possible. To the residue was added diethyl ether (750 mL) which was then filtered to remove the precipitate. The precipitate was washed with diethyl ether (2000 mL). The solvents were removed from the filtrate under reduced pressure to afford the title compound as a colourless oil (41.9 g, 97%). Characterisation data is identical to that reported previously.[12]

N',N''-Bis-(diethyl)methylphosphonate phthalamide (5)

The title compound was isolated as a by-product of the reaction used to synthesise **4**.^[12] X-ray quality crystals were grown by dissolving **5** (0.5 g) in a minimum of dichloromethane in a 20 mL scintillation vial. Diethyl ether (8 mL) was added and the components mixed thoroughly. Hexanes (9 mL) were then added slowly such that a layer of hexanes lay on top of the solution of **5**. The vial was sealed and the layers were allowed to diffuse together at room temperature, affording high quality crystals of **5**. M.p. 119–120°C; ¹H NMR (400 MHz, CDCl₃): δ=1.21 (t, 12H, ³J(H,H)=7 Hz, CH₃), 3.73 (dd, 4H, ²J(H,P)=12 Hz, ³J(H,H)=6 Hz, CH₂P), 3.98 (q, 4H, ³J(H,H)=7 Hz, OCH₂), 4.00 (q, 4H, ³J(H,H)=7 Hz, OCH₂), 7.36 (dd, 2H, ³J(H,H)=6 Hz, ⁴J(H,H)=3 Hz, Ar), 7.48 (dd, 2H, ³J(H,H)=6 Hz, ⁴J(H,H)=3 Hz, Ar), 7.70 ppm (dd, 2H, ³J(H,H)=6 Hz, NH); ¹³C NMR (100 MHz, CDCl₃): δ=16.3 (³J(C,P)=6 Hz, CH₃), 35.2 (¹J(C,P)=156 Hz, CH₂P), 62.4 (²J(C,P)=6 Hz, OCH₂), 128.4 (3-Ar), 130.1 (2-Ar), 134.5 (1-Ar), 168.7 (³J(C,P)=5 Hz, C=O); IR (KBr disc): ν_{max} = 3251 (NH), 3063, 2984, 2931, 2910, 2236 (PO), 1661 (CO) 1595, 1479, 1444, 1369, 1319, 1217 (PO), 1163, 1098, 1023 (PO), 973, 786, 730 cm⁻¹; ESMS-: *m/z* (%): 463 (100) [*M*-H⁺]⁻; elemental analysis calcd (%) for C₁₈H₃₀N₂O₈P₂: C 46.6, H 6.5, N 6.0; found: C 46.1, H 6.4, N 5.9.

(S)-2-(p-Nitrobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetamidomethylene-(diethyl)phosphonate (7)

(S)-2-(p-Nitrobenzyl) cyclen (0.48 g, 1.56 mmol) was dissolved in acetonitrile (20 mL). Potassium carbonate (1.45 g, 11.0 mmol) and bromoacetamide **6** (2 g, 6.94 mmol) were added and the reaction mixture stirred for 72 h at 60 °C. The reaction mixture was filtered and the solvents removed under reduced pressure. The residue was purified by column chromatography over silica gel eluting with 10% methanol in dichloromethane to afford the title compound as pale yellow solid (0.53 g, 30%). ESI+: *m/z* (%): 1136 (35) [*M*+H]⁺, 1158 (100) [*M*+Na]⁺, 1174 (60) [*M*+K]⁺.

(S)-2-(p-Aminobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetamidomethylene-(diethyl)phosphonate (8)

Nitro compound **7** (0.50 g, 0.44 mmol) was dissolved in water (15 mL) and 10% palladium on carbon (0.12 g) was added. The reaction mixture was shaken on a Parr hydrogenation apparatus for 12 h under H₂ (25 psi). The catalyst was removed by filtration and the solvents removed by lyophilization to afford the title compound as a colourless solid (0.35 g, 72%). ESI+: *m/z* (%): 1106 (65) [*M*+H]⁺, 1128 (100) [*M*+Na]⁺.

(S)-2-(p-Isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetamidomethylene-(diethyl)phosphonate (9)

Amine **8** (0.50 g, 0.45 mmol) was dissolved in water (5 mL) and the pH of the resulting solution adjusted to 2 by addition of a dilute HCl solution. Chloroform (15 mL) was added to the reaction which was then stirred vigorously at room temperature. Thiophosgene (0.052 mg, 0.45 mmol) was added to the reaction which was then stoppered and stirred vigorously for 18 h at room temperature. The reaction mixture was then transferred to a separatory funnel and the chloroform layer was allowed to run off. The aqueous layer was then washed with chloroform (2×20 mL). The aqueous layer was then collected and the solvents removed under reduced pressure to afford the title compound as a colourless solid (0.48 g, 93%). ESI+: *m/z* (%): 1148 (100) [*M*+H]⁺, 1170 (78) [*M*+Na]⁺.

(S)-2-(p-Nitrobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetamidomethylene phosphonic acid (2)

Octaethyl ester **7** (0.75 g, 0.66 mmol) was dissolved in a 30% solution of HBr in acetic acid (8 mL). The resulting solution was stirred at room temperature for 18 h. The solvents were

removed under reduced pressure and the residue taken up in EtOH (20 mL), the solvents were again removed under reduced pressure. The solid residue was then taken up into MeOH (10 mL) and the title compound precipitated by dropwise addition of Et₂O. The title compound was isolated by filtration, dissolved in water and the solvents removed by lyophilization to afford a tan solid (0.49 g, 81.4%). ESI+: *m/z* (%): 511 (100) [H₄L+5Na]²⁺.

G5-PAMAM dendrimer–ligand phosphonate diethyl ester conjugate (10)

G5-PAMAM dendrimer (40 mg, 1.4 μmol) was dissolved in DMSO/water 1:1 (4 mL). Isothiocyanate **9** (0.41 g, 0.36 mmol) was added and the pH of the resulting solution raised to 9 by addition of 1M NaOH solution. The reaction was then stirred at 40 °C for 24 h with the pH maintained at 9 by addition of NaOH before a solution of **9** (0.41 g, 0.36 mmol) in DMSO (1 mL) was added. The reaction was stirred for a further 48 h at pH 9. The reaction mixture was then transferred to a Centricon C-30 diafiltration cell with a 30 kD molecular weight cut-off. Diafiltration was repeated until SEC-HPLC revealed that no further low molecular weight material was present, the solvents were then removed by lyophilisation to afford a colourless solid (0.11 g). Anal found C 28.63, S 1.34%, or 56.975 carbon atoms per sulfur atom. The ligand formula C₄₄H₈₁N₉O₁₆P₄S equates to 1 ligand per 12.975 carbon atoms of the dendrimer. The dendrimer formula C₁₂₆₂H₂₅₂₈N₅₀₆O₂₅₂ affords a ratio 1262/12.975 or 97.26 ligands per dendrimer.

G5-PAMAM dendrimer–ligand phosphonic acid conjugate (11)

Conjugate **10** (0.11 g) was dissolved in a 30% solution of HBr/glacial acetic acid (3 mL) under an argon atmosphere. The reaction was stirred at room temperature for 18 h. The solvents were then removed under reduced pressure and residue taken up into methanol (10 mL) which was then also removed under reduced pressure. Dissolution and evaporation of methanol was performed a further three times to remove as much excess acetic acid as possible. The residue was then washed with diethyl and vacuum dried to afford the title compound as a colourless solid (0.09 g).

SEC-HPLC analysis

Size-exclusion HPLC analysis of **10** and Gd**11** were performed on a phenomenex BIOSEP SEC S-3000 size exclusion column (5–700 kD) eluting with PBS buffer at pH 7.4. The column was standardised using commercially available protein (globular) molecular weight standards: cytochrome C (12.4 kD), carbonic anhydrase (29 kD), bovine serum albumin (66 kD), γ-globulins (160 kD), apoferritin (480 kD), dextran blue (2000 kD).

Crystal structure determination of 5

Data collection—A colourless irregular block with approximate orthogonal dimensions 0.46×0.41×0.25 mm was placed and optically centered on the Bruker SMART1000 CCD system (Bruker, SMART, Version 5.054 (2004) and SAINT, Version 7.23 A, Bruker AXS Inc.) at −183 °C. The initial unit cell was indexed using a least-squares analysis of a random set of reflections collected from three series of 0.3° wide ω scans, 10 seconds per frame, and 25 frames per series that were well distributed in reciprocal space. Five ω-scan data frame series were collected (MoK_α) with 0.3° wide scans, 20 seconds per frame and 606 frames collected per series at varying φ angles (φ=0, 72, 144, 216, 288°). The crystal to detector distance was 4.123 cm, thus providing a complete sphere of data to 2θ_{max} = 60.48°.

Structural determination and refinement—A total of 88185 reflections were collected and corrected for Lorentz and polarization effects and absorption using Blessing's method [45] as incorporated into the program SADABS (Sheldrick, G.M., SADABS, Version 2.10 (2003), "Siemens Area Detector Absorption Correction" Universität Göttingen, Göttingen,

Germany) with 13581 unique. The SHELXTL (G. M. Sheldrick, SHELXTL, Version 6.1, 2002, Bruker AXS Inc.) program package was implemented to determine the probable space group and set up the initial files. System symmetry, systematic absences, and intensity statistics indicated the non-centrosymmetric orthorhombic space group $Pna2_1$ (no. 33). The structure was determined by direct methods with the successful location of a majority of the molecule within the asymmetric unit using the program XS (G. M. Sheldrick, SHELXS97 and SHELXL97, 1997), which was also used to refine the structure. The data collected were merged based upon identical indices yielding 53260 data [$R(\text{int})=0.0267$] that were truncated to $2\theta_{\text{max}}=60.00^\circ$ resulting in 51 060 data that were further merged during least-squares refinement to 13 322 unique data [$R(\text{int})=0.0393$]. A series of least-squares difference-Fourier cycles were required to locate the remaining non-hydrogen atoms and optimize the various disorders present for the two molecules in the asymmetric unit. All full occupancy non-hydrogen atoms were refined anisotropically. Hydrogen atoms were idealized throughout the final refinement stages. The final structure was refined to convergence with $R(F)=6.55\%$, $wR(F^2)=12.39\%$, $\text{GOF}=1.118$ for all 13 322 unique reflections [$R(F)=5.72\%$, $wR(F^2)=12.02\%$ for those 11 744 data with $F_o > 4\sigma(F_o)$]. The final difference-Fourier map was featureless indicating that the structure is both correct and complete. An empirical correction for extinction was also attempted but found to be negative and therefore not applied. The absolute structure parameter, $\text{Flack}(x)$, [46] was refined and found to be 0.38(9) indicating that racemic twinning is present.

CCDC 680275 (5) contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

The authors thank the National Institutes of Health (RR-02584, CA-126608 and CA-115531), the Robert A. Welch Foundation (AT-584) for financial assistance.

References

1. Wike-Hooley JL, Haveman J, Reinhold JS. Radiother. Oncol 1984;2:343. [PubMed: 6097949]
2. Tannock IF, Rotin D. Cancer Res 1989;49:4373. [PubMed: 2545340]
3. Vaupel P, Kallinowski F, Okunieff P. Cancer Res 1989;49:6449. [PubMed: 2684393]
4. Khramtsov VV. Curr. Org. Chem 2005;9:909.
5. Woods, M.; Zhang, S.; Kovacs, Z.; Sherry, AD. Advances in Supra-molecular Chemistry. Gokel, G., editor. Vol. 9. Amsterdam: Elsevier; 2003. p. 1 and references therein
6. Aime S, Castelli DD, Terreno E. Angew. Chem 2002;114:4510. Angew. Chem. Int. Ed 2002;41:4334.
7. Aime S, Barge A, Castelli DD, Fedeli F, Mortillaro A, Nielsen FU, Terreno E. Magn. Reson. Med 2002;47:639. [PubMed: 11948724]
8. Woods M, Zhang S, Von Howard E, Sherry AD. Chem. Eur. J 2003;9:4634.
9. Terreno E, Castelli Daniela D, Cravotto G, Milone L, Aime S. Invest. Radiol 2004;39:235. [PubMed: 15021328]
10. Woods M, Kiefer GE, Bott S, Castillo-Muzquiz A, Eshelbrenner C, Michaudet L, McMillan K, Mudigunda SDK, Ogrin D, Tircso G, Zhang S, Zhao P, Sherry AD. J. Am. Chem. Soc 2004;126:9248. [PubMed: 15281814]
11. Aime S, Fedeli F, Sanino A, Terreno E. J. Am. Chem. Soc 2006;128:11326. [PubMed: 16939235]
12. Kalman FK, Woods M, Caravan P, Jurek P, Spiller M, Tircso G, Kiraly R, Brucher E, Sherry AD. Inorg. Chem 2007;46:5260. [PubMed: 17539632]

13. Zhang S, Wu K, Sherry AD. *Angew. Chem* 1999;111:3382. *Angew. Chem. Int. Ed* 1999;38:3192.
14. Bloembergen N. *J. Chem. Phys* 1957;27:572.
15. Bloembergen N, Morgan LO. *J. Chem. Phys* 1961;34:842.
16. Bloembergen N, Purcell EM, Pound RV. *Phys. Rev* 1948;73:679.
17. Solomon I. *Phys. Rev* 1955;99:559.
18. Solomon I, Bloembergen N. *J. Chem. Phys* 1956;25:261.
19. Garcia-Martin ML, Martinez GV, Raghunand N, Sherry AD, Zhang S, Gillies RJ. *Magn. Reson. Med* 2006;55:309. [PubMed: 16402385]
20. Raghunand N, Howison C, Sherry AD, Zhang S, Gillies RJ. *Magn. Reson. Med* 2003;49:249. [PubMed: 12541244]
21. Raghunand N, Zhang S, Sherry AD, Gillies RJ. *Acad. Radiol* 2002;9:S481. [PubMed: 12188315]
22. Borel A, Helm L, Merbach AE. *Chem. Eur. J* 2001;7:600.
23. Botta M. *Eur. J. Inorg. Chem* 2000:399.
24. Ing HR, Manske RHF. *J. Chem. Soc* 1926:2348.
25. Khan MN, Ohayagha JE. *React. Kinet. Catal. Lett* 1996;42:97.
26. Khan MN. *J. Org. Chem* 1996;61:8063. [PubMed: 11667789]
27. Ariffin A, Khan MN, Lan LC, May FY, Yun CS. *Synth. Commun* 2004;34:4439.
28. Khan MN. *J. Org. Chem* 1995;60:4536.
29. Curley OMS, McCormick JE, McElhinney RS, McMurry TBH. *ARKIVOC* 2003:180.
30. Wang SJ, Brechbiel M, Wiener EC. *Invest. Radiol* 2003;38:662. [PubMed: 14501494]
31. Wiener E, Narayanan VV. *Adv. Dendritic Macromol* 2002;5:129.
32. Konda SD, Aref M, Brechbiel M, Wiener EC. *Invest. Radiol* 2000;35:50. [PubMed: 10639036]
33. Wiener EC, Konda S, Shadron A, Brechbiel M, Gansow O. *Invest. Radiol* 1997;32:748. [PubMed: 9406015]
34. Wiener EC, Brechbiel MW, Gansow OA, Foley G, Lauterbur PC. *Polym. Mater. Sci. Eng* 1997;77:193.
35. Wiener EC, Auteri FP, Chen JW, Brechbiel MW, Gansow OA, Schneider DS, Belford RL, Clarkson RB, Lauterbur PC. *J. Am. Chem. Soc* 1996;118:7774.
36. Wiener EC, Brechbiel MW, Brothers H, Magin RL, Gansow OA, Tomalia DA, Lauterbur PC. *Magn. Reson. Med* 1994;31:1. [PubMed: 8121264]
37. Bryant LH Jr, Brechbiel MW, Wu C, Bulte JW, Herynek V, Frank JA. *J. Magn. Reson. Imag* 1999;9:348.
38. Lipari G, Szabo A. *J. Am. Chem. Soc* 1982;104:4546.
39. Lipari G, Szabo A. *J. Am. Chem. Soc* 1982;104:4559.
40. Caravan P, Parigi G, Chasse JM, Cloutier NJ, Ellison JJ, Lauffer RB, Luchinat C, McDermid SA, Spiller M, McMurry TJ. *Inorg. Chem* 2007;46:6632. [PubMed: 17625839]
41. Jaszberenyi Z, Moriggi L, Schmidt P, Weidensteiner C, Kneuer R, Merbach AE, Helm L, Toth E. *J. Biol. Inorg. Chem* 2007;12:406. [PubMed: 17216229]
42. Lebduskova P, Sour A, Helm L, Toth E, Kotek J, Lukes I, Merbach AE. *Dalton Trans* 2006:3399. [PubMed: 16832488]
43. Nicolle GM, Toth E, Schmitt-Willich H, Raduchel B, Merbach AE. *Chem. Eur. J* 2002;8:1040.
44. Laus S, Sour A, Ruloff R, Toth E, Merbach AE. *Chem. Eur. J* 2005;11:3064.
45. Blessing RH. *Acta Crystallogr. Sect. A* 1995;51:33. [PubMed: 7702794]
46. Flack HD. *Acta Crystallogr. Sect. A* 1983;39:876.

Figure 1.
ORTEP rendering of the crystal structure of **5** showing 50% ellipsoids. Hydrogen atoms have been omitted for clarity.

Figure 2.

Relaxivity pH profiles of Gd**1** (◆)[12] Gd**2** (○) and Gd**11** (●) recorded at 20 MHz and 298 K. Relaxivity is expressed per Gd³⁺ ion.

Figure 3. NMRD profiles of Gd11 recorded at pH 6.5 (top) and pH 9.3 (bottom); $\blacklozenge$: 5, $\diamond$: 15, $\bullet$: 25, $\circ$: 35°C.

Figure 4.

Effect of proton residence lifetime (τ_M) on the relaxivity of Gd^{3+} -G5 PAMAM dendrimer conjugates in the fast (top) and slow (bottom) exchange regimes. The simulated profiles are plotted at same scale using parameters: $\tau_g=4.5$ ns, $\tau_l=0.15$ ns, $S^2=0.5$, $\tau_v=20$ ps, $\Delta=2\times 10^9$ s.

Scheme 1.

Synthesis of a functionalised pH responsive contrast agent. i) P(OEt)₃/Δ ii) H₂NNH₂/EtOH; iii) BrCH₂COBr/K₂CO₃/CH₂Cl₂; iv) (*S*)-2-(*p*-nitrobenzyl) cyclen/K₂CO₃/MeCN/60°C; v) 30% HBr in AcOH.

Scheme 2.

Scheme 3.

Synthesis of the dendrimer-based pH responsive contrast agent **Gd11**. i) H_2/Pd on $\text{C}/\text{H}_2\text{O}$; ii) $\text{SCCl}_2/\text{CHCl}_3/\text{H}_2\text{O}$ pH 2; iii) G-5 PAMAM dendrimer/ H_2O pH 8; iv) 30% HBr in AcOH .